GO
Loading...

Amgen Inc

More

  • Final Glance: Biotechnology companies Thursday, 30 Oct 2014 | 6:02 PM ET

    Amgen Inc. rose $2.70 or 1.7 percent, to $161.58. Biogen Idec rose $5.94 or 1.9 percent, to $321.00. Celgene Corp. rose $1.80 or 1.7 percent, to $106.94.

  • Midday Glance: Biotechnology companies Thursday, 30 Oct 2014 | 1:17 PM ET

    Amgen Inc. rose $1.58 or 1.0 percent, to $160.46. Biogen Idec rose $7.39 or 2.3 percent, to $322.45. Celgene Corp. rose $1.80 or 1.7 percent, to $106.94.

  • Early Glance: Biotechnology companies Thursday, 30 Oct 2014 | 11:28 AM ET

    Amgen Inc. fell$. 40 or. 3 percent, to $158.48. Biogen Idec rose$. 43 or. 1 percent, to $315.49. Celgene Corp. fell$. 35 or. 3 percent, to $104.79.

  • Final Glance: Biotechnology companies Wednesday, 29 Oct 2014 | 6:02 PM ET

    Amgen Inc. rose $1.69 or 1.1 percent, to $158.88. Biogen Idec fell $2.97 or. 9 percent, to $315.06. Celgene Corp. fell$. 56 or. 5 percent, to $105.14.

  • Midday Glance: Biotechnology companies Wednesday, 29 Oct 2014 | 1:41 PM ET

    Amgen Inc. rose $1.86 or 1.2 percent, to $159.05. Biogen Idec fell $3.36 or 1.1 percent, to $314.67. Celgene Corp. fell$. 67 or. 6 percent, to $105.03.

  • Early Glance: Biotechnology companies Wednesday, 29 Oct 2014 | 10:53 AM ET

    Amgen Inc. rose$. 90 or. 6 percent, to $158.09. Biogen Idec rose $1.09 or. 3 percent, to $319.12. Celgene Corp. rose$. 43 or. 4 percent, to $106.13.

  • *U.S. dollar softens as market braces for dovish message from Fed. SYDNEY, Oct 29- The U.S. dollar was subdued early on Wednesday as investors waited for the latest guidance from the Federal Reserve, while a surprisingly dovish message from Sweden's central bank saw the crown slump to four-year lows. "In our view, the Riksbank's dovish forward guidance has pushed the...

  • Final Glance: Biotechnology companies Tuesday, 28 Oct 2014 | 6:14 PM ET

    Amgen Inc. rose $8.99 or 6.1 percent, to $157.19. Biogen Idec fell $1.95 or. 6 percent, to $318.03. Celgene Corp. rose $2.60 or 2.5 percent, to $105.70.

  • Twitter and Amgen are big market movers Tuesday, 28 Oct 2014 | 4:42 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Twitter Inc., down $4.78 to $43.78. Regal Entertainment Group, up 77 cents to $21.28.

  • Stocks gain on higher profits, consumer confidence Tuesday, 28 Oct 2014 | 4:11 PM ET

    NEW YORK— Earnings gains and higher consumer confidence numbers sent U.S. stock indexes higher. Amgen rose 6 percent after its earnings beat forecasts. Crude oil rose 42 cents to close at $81.42 a barrel.

  • *Amgen gains, Twitter falls following results. Amgen's stock was up 5.1 percent, among the top boosts for the S&P 500 and Nasdaq, following its results and forecast, while energy shares bounced back sharply from big declines Monday. "Companies are managing to outperform in a period when the global economy is slowing," said Peter Cardillo, chief market economist at...

  • NEW YORK, Oct 28- Amgen Inc, which has come under investor pressure to split the company, said Tuesday it has no plans to do so and forecast 2015 earnings and revenue well ahead of analysts' projections, sending shares up 5 percent. Chief Executive Robert Bradway said the company had considered the option of splitting into mature and growth product businesses- as...

  • US STOCKS-Wall St climbs on earnings, confidence data Tuesday, 28 Oct 2014 | 1:32 PM ET

    *Amgen gains, Twitter falls following results. NEW YORK, Oct 28- U.S. stocks climbed in afternoon trading on Tuesday, following stronger-than-expected earnings and an upbeat consumer confidence reading. Amgen's stock was up 5 percent, among the top boosts for the S&P 500 and Nasdaq, following its results and guidance, while energy shares reboundedbounced back...

  • Midday Glance: Biotechnology companies Tuesday, 28 Oct 2014 | 1:25 PM ET

    Amgen Inc. rose $7.24 or 4.9 percent, to $155.44. Biogen Idec fell $3.28 or 1.0 percent, to $316.70. Celgene Corp. rose $2.18 or 2.1 percent, to $105.28.

  • US STOCKS-Earnings lift Wall St despite mixed data Tuesday, 28 Oct 2014 | 12:00 PM ET

    *Twitter falls; Madison Square Garden up on possible split. *Capital goods orders post largest fall in eight months. Ranking among the largest percentage gainers on the S&P 500 were Amgen, AutoNation and Cummins, which reported earnings between late Monday and Tuesday morning.

  • Amgen plans more job cuts, higher dividend Tuesday, 28 Oct 2014 | 10:56 AM ET

    NEW YORK— Amgen is expanding its plans to cut jobs next year even as it looks to stock repurchases and higher dividends to return about 60 percent of its adjusted earnings to shareholders through 2018.. Amgen Inc. also said that it plans to buy back approximately $2 billion of its shares through the end of 2015. It also plans to increase its dividend by 30 percent...

  • US STOCKS-Wall St up on earnings, data mixed Tuesday, 28 Oct 2014 | 10:52 AM ET

    *Capital goods orders post largest fall in eight months. NEW YORK, Oct 28- U.S. stocks rose on Tuesday as strong earnings and an upbeat consumer confidence reading more than offset weaker-than-expected housing and industrial data. Ranking among the largest percentage gainers on the S&P 500 were Amgen, AutoNation and Cummins, which reported earnings between...

  • Early Glance: Biotechnology companies Tuesday, 28 Oct 2014 | 10:31 AM ET

    Amgen Inc. rose $6.60 or 4.5 percent, to $154.80. Biogen Idec fell $1.10 or. 3 percent, to $318.88. Celgene Corp. rose $2.18 or 2.1 percent, to $105.28.

  • Stocks up as more companies report strong results Tuesday, 28 Oct 2014 | 9:41 AM ET

    NEW YORK— The stock market is moving higher at midday as U.S companies announce positive earnings. The Fed is also winding down its $4 trillion bond-buying program. Amgen rose 6 percent after announcing better-than-expected earnings.

  • Oct 28- Pfizer Inc reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans in the wake of its recent failed efforts to buy rival British drugmaker AstraZeneca Plc. Excluding special items, Pfizer earned 57 cents per share.